What is CG Oncology's EV / sales?

CG Oncology (CGON) reported EV / sales of 1,121.8× in Q1 2026.

How has CG Oncology's EV / sales changed year-over-year?

CG Oncology's EV / sales decreased by 59.3% year-over-year, from 2,758.5× to 1,121.8×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

CG Oncology CGON EV / sales

EV / sales at other companies

PfizerPFE

3.5×+0.3×

Johnson & JohnsonJNJ

6.5×+1.8×

Gilead SciencesGILD

6.3×+0.9×

ImmunityBio, Inc.IBRX

57.9×-33.2×

Tango TherapeuticsTNGX

50.1×+47.1×

Summit TherapeuticsSMMT

8,448.1×+8,132×

Other financials

Income statement

See full

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

See full

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

See full

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

See full

Market cap$5.39B+206%

Profitability

See full

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

See full

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Calculated from CG Oncology’s reported figures.

enterprise value/total revenue=1,121.8×

Based on the most recent quarter.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CG Oncology's EV / sales?: CG Oncology (CGON) reported EV / sales of 1,121.8× in Q1 2026.
How has CG Oncology's EV / sales changed year-over-year?: CG Oncology's EV / sales decreased by 59.3% year-over-year, from 2,758.5× to 1,121.8×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.